Brodalumab

Brodalumab Uses, Dosage, Side Effects, Food Interaction and all others data.

Brodalumab has been used in trials studying the treatment of Asthma, Psoriasis, Crohn's Disease, Psoriatic Arthritis, and Rheumatoid Arthritis. Brodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis.

Increase in the level of IL-17 due to blocking of its receptors.

Table Of contents

• Brodalumab
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Trade Name	Brodalumab
Availability	Prescription only
Generic	Brodalumab
Brodalumab Other Names	Brodalumab
Related Drugs	Humira, Otezla, Cosentyx, methotrexate, Enbrel, Remicade, Stelara, cyclosporine, infliximab
Weight	210mg/1.5ml,
Type	Subcutaneous Solution, Subcutaneous
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country	United States
Last Updated:	September 19, 2023 at 7:00 am

Uses

Brodalumab is a monoclonal antibody used to treat moderate to severe plaque psoriasis.

Brodalumab has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma.

Brodalumab is also used to associated treatment for these conditions: Severe Plaque psoriasis, Moderate Plaque psoriasis

How Brodalumab works

Brodalumab binds with high affinity to interleukin (IL)-17 receptor A, thereby inhibiting several pro-inflammatory cytokines from the IL-17 family.

Food Interaction

No interactions found.

Brodalumab Disease Interaction

Major: Crohn's disease, depression, tuberculosis, vaccinationModerate: infections

Volume of Distribution

4.62 L.

Clearance

0.223 L/day.

Innovators Monograph

You find simplified version here Brodalumab